{"id":249743,"date":"2023-11-29T00:00:00","date_gmt":"2023-11-29T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfim0003-2023-biopharma-scleroderma-systemic-sclerosis-landscape\/"},"modified":"2026-03-31T10:31:48","modified_gmt":"2026-03-31T10:31:48","slug":"nrlfim0003-2023-biopharma-scleroderma-systemic-sclerosis-landscape-forecast-disease-landscape-forecast","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfim0003-2023-biopharma-scleroderma-systemic-sclerosis-landscape-forecast-disease-landscape-forecast\/","title":{"rendered":"Scleroderma (Systemic Sclerosis) &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast"},"content":{"rendered":"<p>Scleroderma, also known as systemic sclerosis (<abbr title=\"systemic sclerosis\">SSc<\/abbr>), is a rare, progressive, and debilitating autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that manifests as Raynaud\u2019s disease, skin thickening, and, often, painful digital ulcers. Mortality risks of pulmonary arterial hypertension (<abbr title=\"pulmonary arterial hypertension\">PAH<\/abbr>), interstitial lung disease (<abbr title=\"interstitial lung disease\">ILD<\/abbr>), and renal crisis are high in <abbr title=\"systemic sclerosis\">SSc<\/abbr> patients. Boehringer Ingelheim\u2019s Ofev (nintedanib) and Roche \/ Genentech\u2019s Actemra \/ RoActemra (tocilizumab) are two of the more-recent therapies specifically targeting the <abbr title=\"systemic sclerosis\">SSc<\/abbr>&#8211;<abbr title=\"interstitial lung disease\">ILD<\/abbr> subpopulation. They have demonstrated the ability to slow the progressive loss of lung function. Other therapies are commonly prescribed off-label for overlapping symptoms. Although the <abbr title=\"systemic sclerosis\">SSc<\/abbr> pipeline is large and diverse, most agents are in early development. Moreover, the development of <abbr title=\"systemic sclerosis\">SSc<\/abbr> therapies has historically been associated with high failure rates, in part due to the heterogeneity of the patient population and the commensurate challenges with trial design.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How large is the diagnosed <abbr title=\"systemic sclerosis\">SSc<\/abbr> population in the United States and <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, and how will it change over the next 10 years?<\/li>\n<li>What is the current treatment landscape in <abbr title=\"systemic sclerosis\">SSc<\/abbr>?<\/li>\n<li>What is the impact of newer-to-market therapies, and how will they change the treatment landscape over the next 10 years?<\/li>\n<li>What do key opinion leaders view as the greatest unmet medical needs in the management of <abbr title=\"systemic sclerosis\">SSc<\/abbr>?<\/li>\n<li>What is the commercial potential of key emerging therapies? How will they fit into the <abbr title=\"systemic sclerosis\">SSc<\/abbr> treatment landscape?<\/li>\n<\/ul>\n<p><strong>Content highlights<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Geographies: United States and <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>.<\/li>\n<li>Primary research: Six country-specific interviews with thought-leading <abbr title=\"systemic sclerosis\">SSc<\/abbr> specialists supported by survey data collected for this study.<\/li>\n<li>Epidemiology: Diagnosed prevalence of <abbr title=\"systemic sclerosis\">SSc<\/abbr> by country, disease severity, and drug-treatment rates.<\/li>\n<li>Forecast: Drug-level sales and patient share of key <abbr title=\"systemic sclerosis\">SSc<\/abbr> therapies through 2032.<\/li>\n<li>Emerging therapies: Phase 3: <span>1<\/span> drug; Phase 1 \/ 2: <span>9 <\/span>drugs.<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Niche &#038; Rare Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution enhancement<\/strong><\/p>\n<p>Niche &#038; Rare Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-249743","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatology","biopharma-therapy-areas-scleroderma-systemic-sclerosis","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249743","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249743\/revisions"}],"predecessor-version":[{"id":576037,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249743\/revisions\/576037"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249743"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}